Nuveen
AQST icon

Nuveen’s Aquestive Therapeutics AQST Stock Holding History

Nuveen’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.06M Buy
1,215,225
+961,760
+379% +$4.05M ﹤0.01% 2090
2026
Q1 		$1.05M Sell
253,465
-110,551
-30% -$449K ﹤0.01% 2566
2025
Q4 		$2.35M Sell
364,016
-180,601
-33% -$1.13M ﹤0.01% 2218
2025
Q3 		$3.04M Buy
544,617
+343,200
+170% +$1.48M ﹤0.01% 2127
2025
Q2 		$667K Sell
201,417
-35,056
-15% -$101K ﹤0.01% 2780
2025
Q1 		$686K Hold
236,473
– – ﹤0.01% 2795
2024
Q4 		$842K Hold
236,473
– – ﹤0.01% 2782
2024
Q3 		$1.18M Sell
236,473
-548,550
-70% -$2.13M ﹤0.01% 2683
2024
Q2 		$2.04M Buy
+785,023
New +$2.62M ﹤0.01% 2386
2021
Q2 		– Sell
-764,217
Closed -$3.97M – 3359
2021
Q1 		$3.97M Buy
764,217
+233,131
+44% +$1.24M ﹤0.01% 2279
2020
Q4 		$2.84M Buy
531,086
+407,332
+329% +$2.44M ﹤0.01% 2331
2020
Q3 		$600K Buy
123,754
+17,399
+16% +$114K ﹤0.01% 2890
2020
Q2 		$516K Buy
+106,355
New +$490K ﹤0.01% 2883

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.8M AUM 25.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Nuveen's AQST Position: Q2 2026 in Review

Nuveen increased its Aquestive Therapeutics (AQST) stake by 379% in Q2 2026, buying an estimated $4.05M and bringing the position to 1,215,225 shares worth $5.06M. The position accounts for ﹤0.01% of the portfolio, ranked #2090.

Nuveen first reported a position in AQST in Q2 2020 and has held it in 13 quarters since. 185 funds tracked by Wall St. Rank hold AQST as of Q2 2026.

  • Nuveen held 1,215,225 shares of Aquestive Therapeutics worth $5.06M as of Q2 2026.
  • Nuveen bought 961,760 Aquestive Therapeutics shares in Q2 2026, an estimated $4.05M.
  • Aquestive Therapeutics made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #2090 holding.
  • Nuveen first reported a position in Aquestive Therapeutics in Q2 2020 and has held it in 13 quarters since.
  • 185 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.